These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 27206569)

  • 1. Pathway-Specific Dopamine Abnormalities in Schizophrenia.
    Weinstein JJ; Chohan MO; Slifstein M; Kegeles LS; Moore H; Abi-Dargham A
    Biol Psychiatry; 2017 Jan; 81(1):31-42. PubMed ID: 27206569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurobiology of dopamine in schizophrenia.
    Guillin O; Abi-Dargham A; Laruelle M
    Int Rev Neurobiol; 2007; 78():1-39. PubMed ID: 17349856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.
    Kegeles LS; Abi-Dargham A; Frankle WG; Gil R; Cooper TB; Slifstein M; Hwang DR; Huang Y; Haber SN; Laruelle M
    Arch Gen Psychiatry; 2010 Mar; 67(3):231-9. PubMed ID: 20194823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies.
    Kambeitz J; Abi-Dargham A; Kapur S; Howes OD
    Br J Psychiatry; 2014 Jun; 204(6):420-9. PubMed ID: 25029687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine-Related Disruption of Functional Topography of Striatal Connections in Unmedicated Patients With Schizophrenia.
    Horga G; Cassidy CM; Xu X; Moore H; Slifstein M; Van Snellenberg JX; Abi-Dargham A
    JAMA Psychiatry; 2016 Aug; 73(8):862-70. PubMed ID: 27145361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of dopamine for the pathophysiology of schizophrenia.
    Meisenzahl EM; Schmitt GJ; Scheuerecker J; Möller HJ
    Int Rev Psychiatry; 2007 Aug; 19(4):337-45. PubMed ID: 17671867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent evidence for dopamine abnormalities in schizophrenia.
    Abi-Dargham A
    Eur Psychiatry; 2002 Aug; 17 Suppl 4():341s-347s. PubMed ID: 23573603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism.
    Carbon M; Ma Y; Barnes A; Dhawan V; Chaly T; Ghilardi MF; Eidelberg D
    Neuroimage; 2004 Apr; 21(4):1497-507. PubMed ID: 15050574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder.
    Volkow ND; Wang GJ; Newcorn J; Telang F; Solanto MV; Fowler JS; Logan J; Ma Y; Schulz K; Pradhan K; Wong C; Swanson JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):932-40. PubMed ID: 17679638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography.
    Laakso A; Vilkman H; Alakare B; Haaparanta M; Bergman J; Solin O; Peurasaari J; Räkköläinen V; Syvälahti E; Hietala J
    Am J Psychiatry; 2000 Feb; 157(2):269-71. PubMed ID: 10671399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET measurements of dopaminergic pathways in the brain.
    Perlmutter JS; Moerlein SM
    Q J Nucl Med; 1999 Jun; 43(2):140-54. PubMed ID: 10429509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presynaptic and postsynaptic nigrostriatal dopaminergic functions in multiple system atrophy.
    Hashimoto M; Kawasaki K; Suzuki M; Mitani K; Murayama S; Mishina M; Oda K; Kimura Y; Ishiwata K; Ishii K; Inoue K
    Neuroreport; 2008 Jan; 19(2):145-50. PubMed ID: 18185098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nature of dopamine dysfunction in schizophrenia and what this means for treatment.
    Howes OD; Kambeitz J; Kim E; Stahl D; Slifstein M; Abi-Dargham A; Kapur S
    Arch Gen Psychiatry; 2012 Aug; 69(8):776-86. PubMed ID: 22474070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences.
    Thobois S; Jahanshahi M; Pinto S; Frackowiak R; Limousin-Dowsey P
    Neuroimage; 2004 Sep; 23(1):1-16. PubMed ID: 15325346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia.
    Caravaggio F; Hahn M; Nakajima S; Gerretsen P; Remington G; Graff-Guerrero A
    Med Hypotheses; 2015 Oct; 85(4):391-6. PubMed ID: 26118462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pure autonomic failure with altered dopamine transporter imaging.
    Compta Y; Martí MJ; Paredes P; Tolosa E
    Arch Neurol; 2006 Apr; 63(4):604-5. PubMed ID: 16606777
    [No Abstract]   [Full Text] [Related]  

  • 17. Heterogeneity in Dopamine Neuron Synaptic Actions Across the Striatum and Its Relevance for Schizophrenia.
    Chuhma N; Mingote S; Kalmbach A; Yetnikoff L; Rayport S
    Biol Psychiatry; 2017 Jan; 81(1):43-51. PubMed ID: 27692238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers.
    Ceravolo R; Antonini A; Volterrani D; Rossi C; Goldwurm S; Di Maria E; Kiferle L; Bonuccelli U; Murri L
    Neurology; 2005 Dec; 65(12):1971-3. PubMed ID: 16380622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study.
    Slifstein M; van de Giessen E; Van Snellenberg J; Thompson JL; Narendran R; Gil R; Hackett E; Girgis R; Ojeil N; Moore H; D'Souza D; Malison RT; Huang Y; Lim K; Nabulsi N; Carson RE; Lieberman JA; Abi-Dargham A
    JAMA Psychiatry; 2015 Apr; 72(4):316-24. PubMed ID: 25651194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET studies of D2-receptor binding in striatal and extrastriatal brain regions: Biochemical support in vivo for separate dopaminergic systems in humans.
    Cervenka S; Varrone A; Fransén E; Halldin C; Farde L
    Synapse; 2010 Jun; 64(6):478-85. PubMed ID: 20175222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.